Company news

Immutep Ltd news in 2024

Immutep Ltd's news releases, calls and decks from 2024, newest first.

View company

Immutep announces initial safety data from IMP761 phase 1

December 16, 2024

Immutep Reports Promising New Data in Head and Neck Cancer

December 11, 2024

Initiation of TACTI-004 phase 3 trial in 1st line NSCLC

December 9, 2024

Excellent Survival Data from INSIGHT-003 Trial in NSCLC

November 13, 2024

Positive Data from Phase II Trial in Soft Tissue Sarcoma

November 13, 2024

Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed

October 3, 2024

Immutep receives A$3.6 million French R&D Tax Incentive

September 23, 2024

New Positive Efficacy Data for Efti in Head and Neck Cancer

September 15, 2024

S&P DJI Announces September 2024 Quarterly Rebalance

September 6, 2024

Appendix 4E & 2024 Full Year Statutory Accounts

August 30, 2024

TACTI-003 data selected for oral presentation at ESMO 2024

August 20, 2024

First Participant Dosed in Phase I Study of IMP761

August 13, 2024

Successful Meeting with FDA on Phase III Design in NSCLC

July 21, 2024

Regulatory Clearance received for Phase 1 trial of IMP761

July 16, 2024

Webcast to discuss data presented at ESMO Plenary Session

July 11, 2024

Positive results in TACTI-003 for 1L HNSCC cohort B patients

July 11, 2024

Webcast slides for new Efti clinical data in 1st line HNSCC

June 26, 2024

Positive topline results from ph2b in head & neck cancer

June 26, 2024

Immutep completes underwritten retail entitlement offer

June 24, 2024

Immutep completes institutional pro-rata offer & placement

June 4, 2024

Immutep announces Ph 3 clinical trial collaboration with MSD

June 3, 2024

Immutep Capital Raising Presentation

June 2, 2024

A$100 million fully underwritten equity raising

June 2, 2024

AIPAC-003 safety lead-in data presented at ESMO Breast 2024

May 15, 2024

Positive initial data in phase 2 Soft Tissue Sarcoma trial

May 1, 2024

Positive preliminary topline results from TACTI-003 Cohort B

April 23, 2024

CHDR to conduct first-in-human phase 1 trial of IMP761

April 17, 2024

First Clinical Data announced from 90mg Dosing of Efti

March 5, 2024

Decks in 2024